Oncology Commercialization
The pace of innovation in oncology is unrivaled by other therapeutic areas. The rapidly evolving science, abundance of targeted therapeutic candidates in the pipeline, rapidly evolving cancer care model and accelerating strain on public and private payment systems all suggest that successful innovation in oncology will require new levels of discipline, sophistication and insight. Breakthrough science alone – while a requirement – is no longer sufficient to guarantee success.
Teams and organizations will need to:
- Translate the potential offered by a pipeline asset into a specific value proposition for a clearly defined and identifiable patient population
- Understand the drivers of therapeutic decision-making and ensure that pivotal studies reflect the current and anticipated real world dynamics, standards and comparators
- Envision specific and compelling label requirements to ensure that the registration program delivers the relevant data
- Anticipate the impact of the proliferating cancer-care pathways
Clarion works with clients to envision the future markets, anticipate product requirements and translate these requirements into action plans. Some services we offer include:
Oncology Landscape Assessments: characterization of how current tumor markets work, therapeutic decisions made, patients managed and specific areas and requirements for future product innovation
New Product Strategy and Profile Development: specific assessment of requirements for a given asset, potential sources of differentiation, data requirements, and implications for the clinical program
Commercialization Planning: integrated roadmap outlining the internal and external priorities to address in the pre-launch and launch phases of a product. Clarion’s seasoned team helps shape, build and pursue activities that will increase the trajectory of the product at launch.
Clarion’s Oncology practice consists of a cross-functional group of professionals with commercial and scientific backgrounds — including PhDs in immunology, biochemistry and cell biology – enabling us to engage deeply with KOLs to gain vital insight into opportunities and challenges within this unique market.
By applying our focused expertise, we help our clients make the best decisions for both their business and the patients they serve.
To learn more about our work in Oncology Commercialization, contact us.